Lanthanum Orifarm

Lanthanum, the active ingredient in Lanthanum Orifarm, is a phosphate binder presented as an oral tablet for oral use. It reduces serum phosphate levels in patients with chronic kidney disease, particularly those undergoing dialysis, and is used to manage hyperphosphatemia and help control mineral‑bone disorder associated with renal impairment.

GNH USA supplies Lanthanum Orifarm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, dialysis units and pharmacies worldwide, adhering to stringent quality standards and providing regulatory documentation for global distribution.

Lanthanum Orifarm is used as a phosphate‑binding agent to control elevated serum phosphate in renal‑related disorders.

- Chronic kidney disease with hyperphosphatemia: lowers serum phosphate to target levels. - End‑stage renal disease on dialysis: reduces phosphate accumulation and assists in mineral balance. - Secondary hyperparathyroidism associated with CKD: helps control phosphate load contributing to parathyroid hormone regulation.

Lanthanum Orifarm may be associated with gastrointestinal and systemic adverse reactions.

Common Side Effects: - Nausea: mild to moderate feeling of sickness. - Constipation: reduced bowel movements. - Diarrhea: loose stools. - Abdominal pain: discomfort in the stomach area.

Serious or Rare Side Effects: - Severe constipation or intestinal obstruction: may require medical intervention. - Allergic reaction: rash, itching, swelling, or anaphylaxis. - Elevated liver enzymes: abnormal hepatic function tests.

When prescribing Lanthanum Orifarm, clinicians should consider the following precautions.

- Monitor serum phosphate: adjust dose to maintain target range. - Assess calcium balance: avoid hypercalcemia when combined with calcium‑based binders. - Evaluate gastrointestinal health: caution in patients with chronic constipation or bowel disorders. - Review concomitant medications: antacids or iron supplements may reduce efficacy. - Pregnancy and lactation: use only if clearly needed, as safety data are limited. - Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture.

Lanthanum Orifarm can interact with several medicines that affect its phosphate‑binding capacity or gastrointestinal absorption.

Major Interactions (Avoid): - Antacids containing aluminum or magnesium: significantly reduce lanthanum binding. - Iron supplements (ferrous sulfate): decrease phosphate binding efficiency. - Calcium carbonate or calcium acetate: compete for binding sites, lowering effectiveness.

Moderate Interactions (Monitor Closely): - Vitamin D analogues (calcitriol, alfacalcidol): may alter calcium‑phosphate balance. - Sevelamer: additive phosphate‑binding effect, monitor serum levels. - Proton pump inhibitors: may affect gastric pH and lanthanum ion release.